Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 6/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ACE | P12821 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
| ▸ | FASN | P49327 | 1/20 | 0.33 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16942396 | 0.91 | PAK1 (0.34) | MMEFFAR4ALDH1A1ACEUSP30 | |
| SCHEMBL19355013 | 0.90 | FFAR4 (0.35) | MMEFFAR4ACEFASNPAK1 | |
| SCHEMBL19376942 | 0.87 | FFAR4 (0.35) | MMEFFAR4ALDH1A1ACEUSP30 | |
| SCHEMBL19331594 | 0.87 | FFAR4 (0.35) | MMEFFAR4ALDH1A1ACEUSP30 | |
| SCHEMBL20364010 | 0.84 | PAK1 (0.35) | MMEFFAR4ACEFASNPAK1 | |
| SCHEMBL29813676 | 0.84 | PAK1 (0.35) | MMEFFAR4ACEFASNPAK1 | |
| SCHEMBL16942417 | 0.84 | PAK1 (0.35) | MMEFFAR4ACEFASNPAK1 | |
| SCHEMBL19376969 | 0.84 | PAK1 (0.35) | MMEFFAR4ACEFASNPAK1 | |
| SCHEMBL24380853 | 0.84 | PAK1 (0.36) | MMEFFAR4ALDH1A1ACEUSP30 | |
| SCHEMBL16983677 | 0.84 | PAK1 (0.36) | MMEFFAR4ALDH1A1ACEUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9839639-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-12-12 | — | — | US | disclosed |
| US-20170189399-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170189399-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885FFAR4 3166/4885ALDH1A1 2655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.